Thomas. Andreas A; Walpurgis. Katja K; Krug. Oliver O; Schänzer. Wilhelm W; Thevis. Mario M
The paper describes a new urine test that can spot tiny amounts of banned peptides like GHRP‑2, showing it can detect as little as a few picograms per milliliter.
Gupta. Deepali D; Chuang. Jen-Chieh JC; Mani. Bharath K BK; Shankar. Kripa K; Rodriguez. Juan A JA;...
In stressed mice, the natural rise in the hunger hormone acyl‑ghrelin depends on β1‑adrenergic receptors. Blocking these receptors with atenolol stops the ghrelin increase and makes depressive‑like behavior worse. Giving extra acyl‑ghrelin or the synthetic GHSR agonist GHRP‑2 does not improve mood under chronic stress.
Thevis. Mario M; Thomas. Andreas A; Schänzer. Wilhelm W
The study shows that modern lab techniques (LC‑MS/MS) can now reliably spot peptide drugs like GHRP‑2, other growth‑hormone‑releasing peptides, insulins and IGF‑1 in blood or urine, even when they’re mixed together. It also explains new tools that make it easier to tell similar‑looking molecules apart.
The study found that the peptide GHRP-2, which is known for boosting growth hormone, also directly triggers the release of ACTH (a hormone that tells the body to make cortisol) in people with pituitary problems, even when other stress tests don’t work.
In rats, giving the peptide GHRP-2 after a rotator cuff tear lowered harmful inflammation and helped the tendon reattach to bone better, making the repair stronger and improving how the animals walked.
Thomas. Andreas A; Delahaut. Philippe P; Krug. Oliver O; Schänzer. Wilhelm W; Thevis. Mario M
Scientists studied how the growth‑hormone‑releasing peptide GHRP‑2 (and similar short peptides) is broken down in the body and how to detect its waste products in urine. They gave the peptide to rats, mixed it with human blood, and used advanced mass‑spectrometry tools to map at least 28 different breakdown products. This work mainly helps anti‑doping labs spot illegal use, rather than telling users how to dose or what benefits to expect.
The paper reviews all the ghrelin‑receptor drugs that have been made, including GHRP‑2. It says that, although many of these compounds have been tested in animals and some in people for things like boosting growth hormone, speeding stomach emptying, or fighting muscle loss, none have become approved medicines except that Japan lets GHRP‑2 be used as a diagnostic tool. New work is now looking at blockers of the same receptor to help with obesity.
In mice, injecting the ghrelin‑like peptide GHRP‑2 directly into the brain reduced pain. The pain‑relief depended on the ghrelin receptor and also involved certain opioid receptors, and GHRP‑2 boosted the effect of morphine. This points to a possible link between the ghrelin system and opioid‑mediated pain control, but the study used a brain injection method that isn’t practical for humans.
In people with non‑functioning pituitary tumors, how much growth hormone (GH) spikes after a GHRP‑2 test tells you how badly the pituitary is damaged and whether GH levels are likely to bounce back after surgery.
In people with non‑functioning pituitary tumors, being overweight makes it harder for the GH‑releasing peptide GHRP‑2 to trigger a strong growth‑hormone surge. Overweight patients were almost four times more likely to have severe GH deficiency, especially when the tumor was larger.
In a rat study, giving the ghrelin‑like peptide GHRP‑2 shortly before a severe bacterial toxin (LPS) reduced lung damage, swelling, and inflammatory chemicals. The protective effect was linked to blocking a key inflammation pathway (NF‑kB). This shows GHRP‑2 can dampen acute inflammation in a very specific, disease‑model setting.
In lab tests on human ovarian cells, the synthetic ghrelin‑like peptide GHRP‑2 lowered inflammation markers that are usually turned on by a strong cell‑activating chemical. It did this by speeding up the breakdown of inflammatory proteins and by dampening several signaling pathways that drive inflammation.
The report describes a single patient with Cushing's disease whose ACTH levels shot up dramatically after a standard GHRP‑2 test. The tumor had the GHRP‑2 receptor, suggesting the peptide can directly boost ACTH in certain pituitary tumors. For most people this isn’t a therapeutic finding, but it shows that GHRP‑2 can strongly affect the stress‑hormone axis.
Kartchner. David D; McCoy. Kevin K; Dubey. Janhvi J; Zhang. Dongyu D; Zheng. Kevin K; Umrani. Rushda...
A big computer‑driven study scanned millions of papers and found that people who had COVID‑19 can develop stubborn high blood pressure. The analysis linked this to several hormone‑related pathways, and even flagged growth‑hormone‑releasing peptide‑2 (GHRP‑2) as one of many molecules that might be involved.
The study shows that the GHRP‑2 test, which is normally used to check growth‑hormone levels, also triggers ACTH (the hormone that tells the adrenal glands to make cortisol). In people with pituitary problems, a weak ACTH response during the test flags secondary adrenal insufficiency, especially when growth‑hormone deficiency is severe.
In a study of short, pre‑pubertal children with growth‑hormone deficiency, a nasal spray of the GH‑releasing peptide GHRP‑2 raised the kids' own GH levels but did not make them grow taller after a year of treatment. The brief spikes in GH were too small to trigger the downstream growth signals needed for height gain.
Okano. Masato M; Sato. Mitsuhiko M; Ikekita. Ayako A; Kageyama. Shinji S
Scientists created a lab test that can spot the peptide GHRP‑2 (also called pralmorelin) and its breakdown product in urine at very low levels. They showed the test works well and that after an IV dose, both the original peptide and its metabolite show up in the urine of all volunteers.
In rat pituitary cells, the study shows that the usual hormone (GHRH) needs its own receptor to trigger growth hormone release, but the peptide GHRP-2 can still cause some GH release even when that receptor is blocked, as long as its own receptor (GHS‑R) is present. Only when both receptors are knocked down does GH release stop completely.
Sinha. Deepankar K DK; Balasubramanian. Adithya A; Tatem. Alexander J AJ; Rivera-Mirabal. Jorge J; Y...
The review says that growth‑ hormone secretagogues (like GHRP‑2) can boost GH and IGF‑1, which might help men with low testosterone lose fat and keep muscle, but there aren’t many solid human studies yet.
Ogawa. Shuichiro S; Matsuzaki. Tomoko T; Noda. Makoto M
Researchers found that a protein called RECK, which sits on cell membranes in the pituitary gland, is important for making growth hormone (GH) and keeping the GH/IGF‑1 system working properly in mice. When RECK levels are lowered, mice get smaller, have less IGF‑1 in their blood, and show reduced GH production and fewer GH‑related receptors, even though the genes for those receptors are more active.